Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
A legfontosabb adatok
- Ki végzi
- Kashiv BioSciences, LLC
- Hol
- Brandon, Brooksville, Miami Lakes és West Lafayette (Egyesült Államok)Mind a 4 helyszín megnézéseMég 2 másik országban, 2 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 600 fő vett részt
- Kezdés
- 2023. aug. 15.
- Befejezés
- 2024. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 10 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Omalizumab Injection
- Xolair Prefilled Syringe
- A regiszteradat frissítve
- 2025. február 5.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Capable of providing written informed consent, adhering to all visit schedules, and meeting study requirements
- Male or female patients 18 to 75 years of age (both inclusive) at the time of screening
- Diagnosis of CIU refractory to H1 antihistamines at the time of randomization, as defined by all of the following:; CIU diagnosis for at least 6 months; Must have been on an approved H1 antihistamine for CIU for at least 3 consecutive days immediately prior to the Day -14 screening visit and must document current use on the day of initial screening; Presence of itch and hives for ≥ 8 consecutive weeks at any time prior to enrollment despite current use of H1 antihistamine treatment; In-clinic UAS ≥ 4 on at least 1 of the screening visit days (Day -14, Day -7, or Day 1); UAS7 (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7 days prior to randomization
- Willing and able to complete a daily symptom diary for the duration of the study and must not have any missing diary entries in the 7 days prior to randomization
- Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study and for 6 months thereafter
- Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone serum levels consistent with postmenopausal status
Ki nem vehet részt
- Participation in a clinical trial involving the administration of an investigational drug or marketed drug within 30 days prior to initial dosing (90 days for biologics)
- Previous treatment with omalizumab within a year prior to screening
- Routine doses of the following medications within 10 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide or investigational agents such as benralizumab or dupilumab etc
- IVIG ( Intravenous immune globulin) or plasmapheresis within 90 days prior to screening
- Regular (daily/every other day) doxepin (oral) use within 14 days prior to screening
- Any H2 antihistamine use within 7 days prior to screening
- Any LTRA (Leukotriene receptor antagonists such as montelukast or zafirlukast) within 10 to 14 days prior to screening
- Evidence of current drug or alcohol abuse
- Evidence of parasitic infection
- Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or any other skin disease associated with itch
- Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved
- Hypersensitivity to omalizumab or any component of the formulation
- History of anaphylactic shock
- Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and/or compromise the safety of the patients
- Positive test for hepatitis B, hepatitis C, or HIV
- History of any clinically significant disease or condition that, in the opinion of the Principal Investigator (PI)/designee, would render them unsuitable for inclusion in the study
- Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study
- Clearly defined underlying etiology for chronic urticarias other than CIU
- Females with positive pregnancy tests at screening or any other visit
- Females who are breastfeeding or lactating
Helyszínek itt: Egyesült Államok
Még 2 másik országban, 2 helyszínen
- True Blue Clinical ResearchBrandon, Egyesült Államok
- Access Research InstituteBrooksville, Egyesült Államok
- San Marcus Research Clinic, Inc.Miami Lakes, Egyesült Államok
- Options Research GroupWest Lafayette, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment
A vizsgálat 10 csoportja
- ADL-018 300 mg Main Treatment periodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
Kezelés: Omalizumab Injection
- Xolair-300 mg Main Treatment PeriodMár használt kezelés, összehasonlításként
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
Kezelés: Xolair Prefilled Syringe
- ADL-018 150 mg Main Treatment periodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
Kezelés: Omalizumab Injection
- Xolair-150 mg Main Treatment PeriodMár használt kezelés, összehasonlításként
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
Kezelés: Xolair Prefilled Syringe
- ADL-018 300 mg Main / ADL-018 300 mg Transition PeriodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to ADL-018 300 mg in the Main Treatment period.
Kezelés: Omalizumab Injection
- Xolair-300 mg Main / ADL-018 300 mg Transition PeriodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
Kezelés: Omalizumab Injection és Xolair Prefilled Syringe
- Xolair-300 mg Main / Xolair-300 mg Transition PeriodMár használt kezelés, összehasonlításként
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
Kezelés: Xolair Prefilled Syringe
- ADL-018 150 mg Main / ADL-018 150 mg Transition PeriodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to ADL-018150 mg in the main treatment period.
Kezelés: Omalizumab Injection
- Xolair-150 mg Main / ADL-018150 mg Transition PeriodA vizsgált kezelés
ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
Kezelés: Omalizumab Injection és Xolair Prefilled Syringe
- Xolair-150 mg Main / Xolair-150 mg Transition PeriodMár használt kezelés, összehasonlításként
XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
Kezelés: Xolair Prefilled Syringe
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of ADL-018 150 mg and 300 mg With US-Licensed Xolair® 150 mg and 300 mg Administered Through Subcutaneous Route Every 4 Weeks in Patients With Chronic Idiopathic Urticaria (CIU) Who Remained Symptomatic Despite Treatment With Approved Doses of H1 Antihistamines
- A regiszteradat frissítve
- 2025. február 5.